earnings
confidence high
sentiment positive
materiality 0.75
NeuroOne Q3 revenue up 105% to $1.7M; net loss narrows to $1.5M; FY25 guidance reaffirmed
NEUROONE MEDICAL TECHNOLOGIES Corp
2025-Q3 EPS
reported -$0.05
vs consensus -$0.24
▲ beat
(+79.6%)
- Product revenue $1.7M, up 105% YoY; gross margin 53.9% (vs 34.1%).
- Net loss $1.5M ($0.03 EPS) vs $2.8M ($0.10 EPS); operating expenses down 9% to $2.8M.
- Oversubscribed $8.2M capital raise closed April 2025; cash $8.0M, no debt.
- FY2025 product revenue guidance $8-10M (132-190% growth); gross margin guidance raised to 50-53%.
- Milestones: FDA 510(k) filed for trigeminal ablation; first patient seizure-free 1-year; sEEG drug delivery order.
item 2.02item 9.01